Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 10/May/2019, 6.44 am

Mechanistic insights into how Vasoactive Intestinal Peptide (PHM27/VIP) attenuates pain: PHM27/VIP, a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 10/May/2019, 6.21 am
May 10, 2019
Vasoactive Intestinal Peptide (PHM27/VIP)-based therapy protects against Cardiomyopathy: Vasoactive Intestinal Peptide (PHM27/VIP), a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 10/May/2019, 7.01 am
May 10, 2019
Show all

Introduction: What they say 

A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.” This research paper was published, in the 1 Nov 2017 issue of the journal “Elife”, by Prof.Kang S, You D and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof.Kang’s research team has recently shown that:(1) DNA methyltransferase 3a (Dnmt3a) promotes insulin resistance; (2) DNMT3a null mice are resistant to diet-induced insulin resistance and glucose intolerance; (3) FGF21 is a negative target of DNMT3a gene and its promoter region is heavily methylated in patients with diabetes; and (4) FGF21 induction attenuates Dnmt3a-mediated insulin resistance, suggesting that decreasing the expression of DNMT3a may result in (a) induction of FGF21; (b) increased insulin sensitivity and glucose tolerance; and (3) attenuation of Obesity-associated TIIDM.


 

From research findings to Therapeutic opportunity:

Given that a number of anticancer agents promote insulin resistance, myocardial dysfunction and so on, identifying an anticancer agent that is free of such side-effects is urgently needed.

This study suggests, for the first time, that anti-cancer agent Bexarotene, by increasing the expression of its target gene, it may decrease the expression of DNMT3a. Thereby, it may: (1) decrease methylation at the FGF21 promoter region; (2) increase FGF21 expression; (3) augment insulin sensitivity; (4) increase glucose tolerance; and (5) inhibit diet-induced insulin resistance (Fig.1).

Figure 1. Mechanistic insights into Cyclin helix B peptide (CHBP) attenuates insulin resistance and cardiac aging. CHBP, by inhibiting DNMT3a expression, induces FGF21 expression, promotes regeneration, attenuates insulin resistance and cardiac aging and promotes longevity

Figure 2. Bexarotene functions as an anti-diabetic agent through induction of FGF21

Thus, pharmacological formulations encompassing Bexarotene or its more safer analogs, either alone or in combination with other drugs,” may be used to treat obesity-associated TIIDM (Fig.2).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does bexarotene decrease the expression of DNMT3a to promote insulin sensitivity?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 10/May/2019, 6.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.